Journal
SCIENCE
Volume 287, Issue 5460, Pages 2020-2022Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/science.287.5460.2020
Keywords
-
Categories
Funding
- NIDA NIH HHS [P01DA10160] Funding Source: Medline
- NIMH NIH HHS [P50MH44866] Funding Source: Medline
Ask authors/readers for more resources
Chronic blockade of dopamine D2 receptors, a common mechanism of action for antipsychotic drugs, down-regulates D1 receptors in the prefrontal cortex and, as shown here, produces severe impairments in working memory. These deficits were reversed in monkeys by short-term coadministration of a D1 agonist, ABT 431, and this improvement was sustained for more than a year after cessation of D1 treatment. These findings indicate that pharmacological modulation of the D1 signaling pathway can produce long-lasting changes in functional circuits underlying working memory. Resetting this pathway by brief exposure to the agonist may provide a valuable strategy for therapeutic intervention in schizophrenia and other dopamine dysfunctional states.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available